International Stem Cell (OTCMKTS:ISCO) Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations. By licensing its cell-based technology, ISCO aims to foster collaboration across the scientific community and accelerate the development of cell therapy and drug discovery platforms worldwide.
Beyond its core stem cell activities, the company markets consumer skin care products under the Lifeline® brand. Leveraging its expertise in human cell biology, ISCO’s skin care portfolio features anti-aging formulations based on cell-conditioned media, peptides and growth factors designed to support skin rejuvenation. These products are distributed through e-commerce channels and selected retail partners in North America, Europe and Asia.
Founded in 2008 and headquartered in Carlsbad, California, International Stem Cell Corporation was co‐founded by Dr. Michael D. West, a veteran in the field of regenerative medicine. The company operates research facilities in California and Australia, reflecting its commitment to global collaboration and the advancement of parthenogenetic stem cell science. Through ongoing R&D efforts and strategic partnerships, ISCO seeks to translate its proprietary hpSC technology into clinical and commercial successes in the emerging cell therapy market.
